[Cytogenetic and statistical study of a group of patients treated with butazolidine (phenylbutazone)].
The authors studied a group of 16 patients suffering from rheumatic diseases, who were being treated with Butazolidine (Phenylbutazone). The control cases were divided into two groups: one consisted of six patients who were suffering from the same chronic rheumatic diseases, but who were being treated with other drugs; the other group consisted of 15 normal persons whose age and sex corresponded, more or less, with those of the group of patients treated with Butazolidine. A chromosomal examination of the lymphocytes of the peripheral blood was carried out on the 16 patients and the 21 persons not being treated with Butazolidine. A comparison of the karyotypes of all the individuals studied showed no significant difference in the number of breakages between the three groups. Statistical analysis confirmed that the differences in the percentages of chromosomal damage were not significant.
D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D002875:Chromosomes / Q000187:drug effects*; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000494:pharmacology*; D012216:Rheumatic Diseases / Q000188:drug therapy
D010653:Phenylbutazone
Etude cytogénétique et statistique d'un groupe de patients traites a la butazolidine (phenylbutazone)